drugset / Trial / NCT05376423
To Evaluate OBI-833/OBI-821 in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer for Recurrence
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase 2 Study to Evaluate Adjuvant OBI-833/OBI-821 Therapy in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer at High Risk for Recurrence
Timeline
- Start
- 2022-06-02
- Primary completion
- 2024-12
- Completion
- 2025-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OBI-821 | Other / unclassified | 100 ug | Subcutaneous |
| Subject | OBI-833 | Vaccine | 30 ug | Subcutaneous |